Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy

Christine Bouchardy1*, Alfredo Morabia2, Helena M Verkooijen1, Gérald Fioretta1, Yves Wespi3 and Peter Schäfer4

Author Affiliations

1 Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, 55 boulevard de la Cluse, 1205 Geneva, Switzerland

2 Division of Clinical Epidemiology, Geneva University Hospitals, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland

3 Group of Gynecologists and Obstetricians Geneva, Association of Physicians of the Canton of Geneva, 8, rue Saint-Leger, 1205 Geneva, Switzerland

4 Clinic of Gynecology, Senology, Department of Obstetrics and Gynecology, Geneva University Hospitals, 30 boulevard de la Cluse, 1211 Geneva 14, Switzerland

For all author emails, please log on.

BMC Cancer 2006, 6:78  doi:10.1186/1471-2407-6-78

Published: 22 March 2006

Abstract

Background

This article aims to explain the reasons for the remarkable change in age of breast cancer occurrence in the Swiss canton of Geneva.

Methods

We used population-based data from the Geneva cancer registry, which collects information on method of detection, stage and tumour characteristics since 1975. For patients diagnosed between 1997–2003, we obtained additional information on use of hormone replacement therapy from a large prospective study on breast cancer. Using generalized log linear regression analysis, we compared age-specific incidence rates with respect to period, stage, oestrogen receptor status, method of detection and use of hormone replacement therapy.

Results

In the periods 1975–1979 and 1985–1989, breast cancer risk increased with age, showing the highest incidence rates among women aged ≥ 85 years. From 1997, the age-specific incidence curve changed completely (p < 0.0001), showing an incidence peak at 60–64 years and a reduced incidence among elderly women. This incidence peak concerned mainly early stage and oestrogen positive cancers and was exclusively observed among women who ever used hormone replacement therapy, regardless whether the tumour was screen-detected or not.

Conclusion

The increasing prevalence of hormone replacement therapy use during the 1990s could explain the important change in age-specific breast cancer incidence, not only by increasing breast cancer risk, but also by revealing breast cancer at an earlier age.